WebMar 29, 2024 · The purpose of this review is to collect the current evidence regarding application and limits of different therapeutic approaches for preventing postoperative recurrence of pterygium, giving insights and perspectives for … WebFeb 20, 2011 · This treatment modality warrants additional investigation in a phase III setting. Phase II study of conformal hypofractionated radiotherapy with concurrent …
Prostatakarzinom Knochenmetastasen springermedizin.de
WebMay 20, 2011 · BRAF tumor mutation is an indicator of poor prognosis. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal … WebSep 21, 2016 · Purpose TAK-733, an investigational, selective, allosteric MEK1/2 inhibitor, has demonstrated antitumor effects against multiple cancer cell lines and xenograft models. This first-in-human study investigated TAK-733 in patients with solid tumors. Methods Patients received oral TAK-733 once daily on days 1–21 in 28-day treatment cycles. … chaudfontaine water glazen fles
Risk of venous and arterial thromboembolic events associated …
WebSep 10, 2011 · J Clin Oncol. 2011 Sep 10;29(26):3574-9. doi: 10.1200/JCO.2011.35.9638. Epub 2011 Aug 8. Authors Antonio Marchetti 1 , Lara Felicioni, Sara Malatesta, Maria Grazia ... 0.9%), as indicated by multivariate logistic regression analysis (hazard ratio [HR], 11.29; P < .001). V600E-mutated tumors showed an aggressive histotype characterized by ... WebHainsworth JD, Spigel DR, Greco FA, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous … WebSep 20, 2011 · J Clin Oncol. 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. ... Eastern Cooperative Oncology Group performance status ≤ 2) were randomly assigned to carboplatin area under the curve (AUC) 5 plus paclitaxel 175 mg/m(2) or to carboplatin AUC 5 plus PLD 30 mg/m(2), every 3 weeks for six cycles. Primary end point was progression … custom made wine cellar